Moreover, the 36-month beta value for MIST is 1.72. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MIST is 50.39M and currently, short sellers hold a 0.75% of that float. On August 22, 2024, MIST’s average trading volume was 122.80K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
MIST) stock’s latest price update
Milestone Pharmaceuticals Inc (NASDAQ: MIST)’s stock price has gone rise by 4.29 in comparison to its previous close of 1.40, however, the company has experienced a 8.15% increase in its stock price over the last five trading days. globenewswire.com reported 2024-08-08 that – NDA for CARDAMYST™ in PSVT accepted by FDA in 2Q 2024; PDUFA in March 2025 – Cash of $83.3 million as of June 30, 2024 expected to fund operations into 2026 – Stuart Duty and Andrew Saik Appointed as Independent Board Directors MONTREAL and CHARLOTTE, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) — Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the second quarter ended June 30, 2024 and provided a regulatory and corporate update.
MIST’s Market Performance
Milestone Pharmaceuticals Inc (MIST) has experienced a 8.15% rise in stock performance for the past week, with a -1.35% drop in the past month, and a -16.57% drop in the past quarter. The volatility ratio for the week is 6.25%, and the volatility levels for the past 30 days are at 5.22% for MIST. The simple moving average for the past 20 days is 4.47% for MIST’s stock, with a -18.32% simple moving average for the past 200 days.
Analysts’ Opinion of MIST
Jefferies, on the other hand, stated in their research note that they expect to see MIST reach a price target of $4, previously predicting the price at $8. The rating they have provided for MIST stocks is “Hold” according to the report published on June 20th, 2023.
Piper Sandler gave a rating of “Overweight” to MIST, setting the target price at $10 in the report published on April 22nd of the previous year.
MIST Trading at 3.09% from the 50-Day Moving Average
After a stumble in the market that brought MIST to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.52% of loss for the given period.
Volatility was left at 5.22%, however, over the last 30 days, the volatility rate increased by 6.25%, as shares sank -0.68% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.77% upper at present.
During the last 5 trading sessions, MIST rose by +9.62%, which changed the moving average for the period of 200-days by -47.33% in comparison to the 20-day moving average, which settled at $1.3970. In addition, Milestone Pharmaceuticals Inc saw -12.57% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for MIST
Current profitability levels for the company are sitting at:
- 57.03 for the present operating margin
- 1.7 for the gross margin
The net margin for Milestone Pharmaceuticals Inc stands at 55.77. The total capital return value is set at -0.58. Equity return is now at value -133.75, with -51.98 for asset returns.
Based on Milestone Pharmaceuticals Inc (MIST), the company’s capital structure generated 0.62 points at debt to capital in total, while cash flow to debt ratio is standing at -0.7. The debt to equity ratio resting at 1.63. The interest coverage ratio of the stock is -29.41.
Currently, EBITDA for the company is -60.81 million with net debt to EBITDA at -0.84. When we switch over and look at the enterprise to sales, we see a ratio of -136.29. The receivables turnover for the company is -0.36for trailing twelve months and the total asset turnover is -0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 19.13.
Conclusion
To wrap up, the performance of Milestone Pharmaceuticals Inc (MIST) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
